Log in with your email address username.


[Correspondence] Inhaled triple therapy in chronic obstructive pulmonary disease – Authors’ reply

We thank Eric Marchand for his comment and query. On the basis of previous studies,1,2 Marchand questions whether the withdrawal of inhaled corticosteroids (ICS) in a proportion of patients randomised to a combination of a long-acting β-agonist and a long-acting anticholinergic (LABA/LAMA) in the TRIBUTE study3 could be responsible for the observed difference in moderate-to-severe exacerbation rates. To address this issue, we have done a stratified analysis according to previous use of ICS/LABA and LABA/LAMA in the 2 months before screening.